Latest Lupin Ltd. Stories
ARDEE, Ireland, Oct. 14 /PRNewswire/ -- Warner Chilcott plc (Nasdaq: WCRX) and its subsidiary, Warner Chilcott Company, LLC, and Lupin Ltd.
BALTIMORE, Aug. 3 /PRNewswire/ -- Lupin Ltd. today announced the appointment of Paul McGarty as President of its U.S. Subsidiary, Lupin Pharmaceuticals, Inc.
MUMBAI, India, Jan. 20 /PRNewswire/ -- Pharma major, Lupin Ltd announced today that it has received official communication from the US FDA on the satisfactory resolution of the Warning Letter issued earlier to its Mandideep site.
MUMBAI, India, Oct. 5 /PRNewswire-FirstCall/ -- Pharma Major, Lupin Ltd today announced that it has granted Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) the exclusive rights for the United States to its bioadhesive drug delivery technology for use with Rifaximin.
MUMBAI, India, Sept. 29 /PRNewswire-FirstCall/ -- Pharmaceutical Major, Lupin Ltd. announced today the acquisition of US rights for AntaraÂ® (Fenofibrate Capsules 43 mg and 130 mg). Lupin acquired the product from Oscient Pharmaceuticals on September 25, 2009, under the procedures of the U.S.
ARDEE, Ireland, Aug. 3 /PRNewswire-FirstCall/ -- Warner Chilcott Limited (Nasdaq: WCRX) announced today that it has received two Paragraph IV Certification Notices from Lupin Ltd. ("Lupin").
MUMBAI, India, Dec. 17 /PRNewswire/ -- Pharma Major, Lupin Ltd. announced today that it has settled all ongoing Hatch-Waxman litigation relating to Desloratadine tablets, the generic version of Schering-Plough's "Clarinex"(R) tablets. As per the terms of the settlement, Lupin Ltd.
MUMBAI, India and BALTIMORE, Aug. 19 /PRNewswire/ -- Lupin Ltd. announced today that the Company has entered into a multi-year promotion and marketing agreement for the AeroChamber Plus(R) line of products with Forest Laboratories, Inc.